Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 15/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201096 | 0.94 | HTR1A (0.64) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6202240 | 0.91 | HTR1A (0.54) | HTR1ASLC6A4DRD2HTR2AHTR6 | |
| SCHEMBL6200972 | 0.90 | HTR1A (0.55) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL6202163 | 0.90 | HTR1A (0.53) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6202798 | 0.88 | HTR1A (0.73) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL7038637 | 0.87 | HTR1A (0.49) | HTR1ASLC6A4KDM4EDRD2 | |
| SCHEMBL6203852 | 0.87 | HTR1A (0.68) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL5767215 | 0.83 | HTR1A (0.72) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL5766210 | 0.82 | HTR1A (0.75) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6628542 | 0.82 | HTR1A (0.72) | HTR1ASLC6A4KDM4ELMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401839-B9 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA [A] NAPHTHALENE | WYETH CORP (US) | 2005-11-30 | — | — | EP | claimed |
| EP-1401839-B1 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA [A] NAPHTHALENE | WYETH CORP (US) | 2005-09-07 | — | — | EP | claimed |
| EP-1401839-A1 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA A]NAPHTHALENE | Wyeth (US) | 2004-03-31 | — | — | EP | claimed |
| US-6573283-B2 | For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse | WYETH | 2003-06-03 | — | — | US | claimed |
| US-20020183351-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene | WYETH (US) | 2002-12-05 | — | — | US | claimed |
| WO-2002088131-A1 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA[A]NAPHTHALENE | WYETH (US) | 2002-11-07 | — | — | WO | claimed |
| EP-1401839-B9 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA [A] NAPHTHALENE | WYETH CORP (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1401839-B1 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA [A] NAPHTHALENE | WYETH CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6927226-B2 | Antidepressant azaheterocyclymethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene | WYETH (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1401839-A1 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA A]NAPHTHALENE | Wyeth (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20040010006-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene | WYETH | 2004-01-15 | — | — | US | disclosed |
| US-6573283-B2 | For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse | WYETH | 2003-06-03 | — | — | US | disclosed |
| US-20020183351-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene | WYETH (US) | 2002-12-05 | — | — | US | disclosed |
| WO-2002088131-A1 | ANTIDEPRESSANT (SSSRI) AZAHETEROCYCLYMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-T,9-DIOXA-1,3-DIAZACYCLOPENTA[A]NAPHTHALENE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010006-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene | OPRD1, OPRK1, HSD17B11 | HTR1A 9/4885SLC6A4 198/4885KDM4E 1904/4885 |
| US-20020183351-A1 | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene | OPRD1, OPRK1, HSD17B11 | HTR1A 9/4885SLC6A4 198/4885KDM4E 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.